This node covers the drug-channel plumbing that moves prescription medicines, specialty therapies, medical supplies, dental products, pharmacy claims, and patient-access services from manufacturers to pharmacies, health systems, physician practices, employers, insurers, and patients. The physical and operating stack includes wholesaler distribution centers, cold-chain and specialty handling, generic sourcing programs, oncology and multispecialty practice services, mail and retail pharmacy locations, PBM claims systems, pharmacy software, receivables funding, and practitioner supply routes. The current basket read is that MCK and CAH have the cleanest current distributor evidence, COR has the best local knowledge support but a customer-term and cash-conversion burden, CVS is an access route with PBM and retail margin risk, and HSIC is an office-care distribution tail with less direct prescription-drug exposure.
What the stack is: drug access and distribution is the channel between drugmakers, pharmacies, hospitals, physician practices, payers, employers, dental offices, and patients.
What it does: it purchases, stores, routes, finances, adjudicates, dispenses, and supports access to medicines and related clinical supplies while managing payer rules, manufacturer terms, rebates, chargebacks, inventory, and receivables.
Main pieces: wholesale distribution centers, specialty-drug logistics, oncology and multispecialty provider platforms, generic sourcing programs, retail and mail pharmacies, PBM claims and network systems, prescription-technology tools, dental and medical supply catalogs, and working-capital funding.
Where it sits: operationally between manufacturers and the care site; physically in warehouses, cold-chain routes, pharmacies, practice offices, and claims systems; financially in inventory, accounts receivable, accounts payable, rebates, dispensing margin, and service fees.
How the theme uses it: aging, chronic disease, oncology, diabetes, dental care, and office-based medicine create more prescription and supply flow. The investable question is whether that flow becomes segment operating profit, free cash flow, and durable customer terms after reimbursement, PBM, inventory, and debt costs.
Terms used later: specialty distribution means high-touch handling and provider support for complex therapies; PBM means pharmacy benefit manager, the claims and formulary gatekeeper for drug benefits; generic sourcing spread is the margin from buying generic drugs efficiently; working-capital conversion tests whether inventory and receivables turn into cash rather than only reported revenue.
Report boundary: this node is a tactical report layer. It ranks the current value-chain basket, setup labels, confirmation triggers, invalidation levels, and chart provenance. Durable research, raw source registries, and company thesis maintenance stay in the linked knowledge pages. Price and volume context comes from read-only discovery daily_ohlc through 2026-06-12.
Current Setup
Distribution conversion gateMore scripts matter only when margin, cash flow, and customer terms hold.
Wholesalers and pharmacy access platforms have large revenue bases but thin profit rates. The useful evidence is segment profit, free cash flow, receivables, inventory, pharmacy margin, and customer retention.
Positive proofMCK and CAH have the cleanest current prints.
MCK reported $96.3B of Q4 FY2026 revenue; CAH reported $60.9B of Q3 FY2026 revenue and higher adjusted FCF guidance.
Conversion gateCOR, CVS, and HSIC need cleaner cash or margin follow-through.
COR has strong local specialty-distribution support; CVS and HSIC must prove non-HCB pharmacy and practice volume become profit and cash.
Primary constraintReimbursement and working capital can absorb volume.
Watch customer losses, GLP-1 mix, PBM remedies, receivables, inventory funding, pharmacy closures, and debt-funded acquisitions.
Demand sourceAging + chronic care
Channel workBuy, route, adjudicate
Collection routeFees, spread, scripts
Proof pointEBIT, FCF, terms
Aging, chronic disease, oncology, diabetes, specialty therapies, dental care, and office-based medicine all create more product flow. This node asks whether the channel keeps any of the economics after reimbursement pressure, manufacturer terms, customer terms, rebates, inventory funding, and debt service. The useful evidence is segment operating profit, free cash flow, DSO/DPO, inventory days, prescription margin, pharmacy closures, and customer retention.
MCK has the strongest current source-backed distributor evidence, with FY2026 revenue of $403.4B, free cash flow of $5.4B, North American Pharmaceutical revenue of $336.7B, and Oncology & Multispecialty revenue of $48.4B. CAH reported Q3 FY2026 revenue of $60.9B, Pharmaceutical and Specialty Solutions revenue of $56.1B, segment profit of $784M, and a higher adjusted free-cash-flow guide. COR gives the page a locally sourced U.S. Healthcare Solutions and specialty-platform route. CVS adds Caremark, specialty, mail, and retail pharmacy access; HSIC adds dental and medical practice distribution. The next positive proof is distributor segment EBIT growing with operating cash flow, pharmacy volume converting to profit, and weekly closes holding or reclaiming trend levels.
Thin wholesale margins leave little room for customer losses, worse contract terms, GLP-1 or specialty revenue without profit, reimbursement cuts, PBM remedies, receivable concentration, inventory funding, or debt-funded acquisitions. CVS showed higher prescription volume while Health Services and Pharmacy & Consumer Wellness adjusted operating income declined in Q1 2026. HSIC still needs internal growth, GAAP margin, and operating cash flow recovery. MCK and CAH also lack filed local security lanes, while WBA and PDCO have no active local instrument or OHLC after take-private transactions. Watch customer concentration, cash conversion, full-year free cash flow, pharmacy closures, and PBM or Medicare policy updates before treating drug volume as shareholder value.
Static setup labels were built from weekly bars aggregated from discovery daily_ohlc through 2026-06-11. The local report API now has chart data through 2026-06-12, so refresh static setup thresholds before using them as current trading evidence. Fundamental claims route to the Health Care sector lane, the reimbursement-dispersion theme, linked security lanes, and official company or SEC releases for names without local security lanes.
Basket
This basket is inherited from the parent theme and ranked inside the node by direct distribution/access economics, current official-source evidence, local knowledge support, cash-conversion evidence, and then technical timing. MCK and CAH rank first because they have the clearest current distributor revenue and profit evidence; COR ranks third because local knowledge is strong but the cash-conversion and customer-term tests are higher; CVS and HSIC remain useful access routes with less pure drug-wholesale exposure.
MCKMcKesson
Scaled drug distributor and specialty access platform with the clearest current official-source revenue, segment profit, and free-cash-flow evidence.
Market cap$88.3B
Next earningsAug 5, 2026 est.
Latest qtr revenue$96.3B
Role in stack
McKesson sells and routes pharmaceuticals, specialty drugs, oncology support, prescription technology, and medical-surgical supplies to pharmacies, health systems, oncology practices, manufacturers, employers, payers, and government customers. The conversion path is distribution fees, specialty handling, provider services, generic sourcing, prescription-technology revenue, working-capital discipline, and free cash flow.
Revenue mix
FY2026 revenue was $403.4B: North American Pharmaceutical $336.7B, Oncology & Multispecialty $48.4B, Prescription Technology Solutions $5.8B, and Medical-Surgical Solutions $11.5B.
Latest qtr revenue
Fiscal Q4 2026 revenue for the quarter ended March 31, 2026 was $96.3B. Segment detail came from McKesson's May 7, 2026 fiscal 2026 results release; no filed local MCK security lane exists yet.
CAHCardinal Health
Pharmaceutical and specialty distributor with a fresh Q3 FY2026 operating print and visible adjusted free-cash-flow guide.
Market cap$43.0B
Next earningsNot confirmed
Latest qtr revenue$60.9B
Role in stack
Cardinal Health distributes pharmaceuticals, specialty products, medical products, at-home supplies, and provider-platform services to pharmacies, providers, hospitals, and other care sites. Theme pressure converts through pharma and specialty volume, generics program performance, specialty services, medical-product recovery, inventory discipline, and free cash flow.
Revenue mix
Q3 FY2026 revenue was $60.9B. Pharmaceutical and Specialty Solutions generated $56.1B, Global Medical Products and Distribution generated $3.1B, and Other generated $1.7B.
Latest qtr revenue
Fiscal Q3 2026 revenue for the quarter reported April 30, 2026 was $60.9B. The SEC-filed earnings exhibit also showed Pharmaceutical and Specialty Solutions profit of $784M and non-GAAP operating earnings of $956M.
Large U.S. pharmaceutical distributor with local specialty-platform evidence and a live customer-term and cash-conversion test.
Market cap$50.8B
Next earningsAug 5, 2026 est.
Latest qtr revenue$78.4B
Role in stack
Cencora serves pharmacies, providers, physician practices, manufacturers, and international wholesale/logistics customers. Distribution scale, specialty products, provider platforms, GLP-1 and chronic-drug volume, receivable discipline, and adjusted free cash flow decide whether volume becomes equity value.
Revenue mix
Q2 FY2026 revenue was $78.4B. U.S. Healthcare Solutions was the dominant segment; the local lane also tracks International Healthcare Solutions, Other, RCA, OneOncology, EyeSouth, Walgreens exposure, and working-capital quality.
Latest qtr revenue
Fiscal Q2 2026 revenue for the quarter ended March 31, 2026 was $78.4B. Cencora's May 6, 2026 release and the COR knowledge lane show a lowered FY2026 revenue-growth guide, higher adjusted operating-income guide, and about $3.0B adjusted FCF target.
Integrated pharmacy access and PBM route where prescription volume must convert into Health Services and retail pharmacy profit.
Market cap$115.5B
Next earningsJul 30, 2026 est.
Latest qtr revenue$100.4B
Role in stack
CVS connects Aetna benefits, Caremark PBM services, specialty and mail pharmacy, retail pharmacy, infusion, and consumer pharmacy. The node economics depend on PBM contract terms, retail reimbursement, script volume, specialty mix, Aetna medical-cost control, debt service, and operating cash flow.
Revenue mix
Q1 2026 revenue was $100.4B. Health Services revenue was $48.2B, Pharmacy & Consumer Wellness was $32.0B, and Health Care Benefits was $36.0B. Pharmacy & Consumer Wellness filled 451.2M prescriptions.
Latest qtr revenue
Q1 2026 revenue for the quarter ended March 31, 2026 was $100.4B. CVS's May 6, 2026 release showed prescription volume growth, but Health Services adjusted operating income fell 7.1% and Pharmacy & Consumer Wellness adjusted operating income fell 8.8%.
Office-based dental and medical distribution route with useful access exposure and a lower direct prescription-drug fit.
Market cap$8.1B
Next earningsAug 4, 2026 est.
Latest qtr revenue$3.368B
Role in stack
Henry Schein supplies dental and medical practitioners, clinics, and specialty-product customers. Demand converts through dental merchandise and equipment, medical distribution, specialty products, technology, e-commerce, value-added services, internal growth, margin, and cash conversion.
Revenue mix
Q1 2026 net sales were $3.368B. Global Distribution and Value-Added Services was 84.3% of sales, Global Specialty Products was 11.8%, and Global Technology was 5.1%.
Latest qtr revenue
Q1 2026 net sales for the quarter ended March 28, 2026 were $3.368B. The HSIC knowledge lane flags 2.5 percentage points of internal growth, negative Q1 operating cash flow, and about $3.4B of total debt as the live quality checks.
Market caps use read-only discovery instruments.market_cap queried on 2026-06-13. Nasdaq/Zacks estimated next-earnings dates checked on 2026-06-13: MCK Aug 5, 2026 est.; COR Aug 5, 2026 est.; CVS Jul 30, 2026 est.; HSIC Aug 4, 2026 est. CAH is marked Not confirmed because this worker did not obtain a credible current earnings-date source. Source-only and watch list: WBA is a private retail-pharmacy stress and COR-customer watch after its August 2025 transaction; PDCO is a private dental and animal-health distribution comp after its April 2025 transaction. CI and OPCH are adjacent public access names for a future broader PBM or home-infusion pass, but they are outside the core parent basket for this node.
What Confirms Or Weakens
AreaWhat confirmsWhat weakens or invalidatesWatch next
01Node thesis
Volume becomes cash
What confirms
Drug and supply volume converts into segment operating income, operating cash flow, free cash flow, and stable customer terms.
What weakens or invalidates
Revenue grows while gross profit rate, operating income, inventory days, receivables, payables, or cash flow deteriorate.
Watch next
Segment EBIT
OCF and FCF
DSO/DPO
Inventory turns
02Wholesaler economics
Thin-margin conversion
What confirms
MCK, CAH, and COR grow specialty, oncology, pharmacy-services, generics, and prescription-technology contribution while maintaining receivable and inventory discipline.
Large customers renew without worse economics, specialty and oncology platforms retain providers, and retail or mail pharmacy volume converts into gross profit per script.
What weakens or invalidates
Walgreens or other customer terms deteriorate, PBM remedies compress Caremark economics, pharmacy closures reduce access, or provider-platform integration weakens retention.
Watch next
Walgreens exposure
PBM updates
Pharmacy closures
Provider retention
04Funding and cash
Working capital clears
What confirms
Operating cash flow covers capex, acquisitions, dividends, buybacks, and debt service without higher intra-period borrowing or receivable stress.
05Policy and reimbursement
Margin rules do not tighten
What confirms
Medicare, PBM, pharmacy reimbursement, generic sourcing, and specialty access rules leave distributors and access platforms with stable profit pools.
What weakens or invalidates
PBM transparency remedies, Part D economics, client repricing, retail reimbursement cuts, or generic-price deflation reduce profit per claim or per script.
Watch next
Medicare/PBM policy
Caremark contracts
Generic sourcing
Retail reimbursement
06Stale condition
Refresh trigger
What confirms
MCK and CAH get filed local security lanes, official company releases remain current, and local OHLC stays current for the five charted names.
What weakens or invalidates
The page relies on official earnings snippets without durable knowledge routing, WBA or PDCO re-enter charted lists without active local OHLC, or new releases arrive before refresh.
Cardinal Health Q3 FY2026 results exhibit for CAH Q3 FY2026 revenue of $60.9B, Pharmaceutical and Specialty Solutions segment profit, non-GAAP operating earnings, and adjusted free-cash-flow guidance.
Cencora Q2 FY2026 results for COR Q2 FY2026 revenue of $78.4B, U.S. Healthcare Solutions, segment operating income, and FY2026 guide.
CVS Q1 2026 results for CVS Q1 2026 revenue of $100.4B, Health Services, Pharmacy & Consumer Wellness, prescription volume, and adjusted operating income.
Henry Schein Q1 2026 financial results for HSIC Q1 2026 net sales of $3.368B, Global Distribution and Value-Added Services, Specialty Products, and Technology growth.
Next-earnings estimates were checked on 2026-06-13 through Nasdaq API endpoints /api/analyst/MCK/earnings-date, /api/analyst/COR/earnings-date, /api/analyst/CVS/earnings-date, and /api/analyst/HSIC/earnings-date. Nasdaq states those dates are algorithmic estimates based on historical reporting dates and its Zacks Investment Research vendor, so the Basket labels them est..
Estimated next earnings: MCK Aug 5, 2026; COR Aug 5, 2026; CVS Jul 30, 2026; HSIC Aug 4, 2026. CAH is marked Not confirmed because no credible earnings-date source was obtained in this worker pass.
Market caps use read-only discovery instruments.market_cap queried on 2026-06-13: MCK $88.3B, CAH $43.0B, COR $50.8B, CVS $115.5B, and HSIC $8.1B.
Discovery And Chart Provenance
DuckDB source: /home/nick/projects/portfolio-manager/discovery/data/discovery.duckdb, opened read-only for status, market cap, and weekly setup work.
Discovery status found daily_ohlc through 2026-06-12 for MCK, CAH, COR, CVS, and HSIC; WBA and PDCO had no local instrument or OHLC rows in the prior page package.
Weekly setup rows aggregate daily rows by calendar week using first open, maximum high, minimum low, final close, and summed volume. Indicators use 20W and 100W EMAs computed from weekly closes with full available local history.
Selected-security charts use the local report API route /api/securities/{ticker}/chart?frequency=weekly&window=3y&as_of=latest. This page does not embed full OHLC arrays.
Representative API check should use the same route for a charted ticker, for example /api/securities/MCK/chart?frequency=weekly&window=3y&as_of=latest. If the local report API is down, the selected-security rail should show its API-unavailable state.
Subagent Tournament
The page uses the requested 10 primary subagent research pass plus one merge/select pass. The final merge kept a distributor-first core basket and rejected CI, OPCH, UNH, ELV, OMCL, GDRX, and payer or automation adjacencies from the core.
The merge selected MCK, CAH, COR, CVS, and HSIC as the final rank, with CI and OPCH as adjacent watch names and WBA/PDCO as source-only status names.
Known Gaps
MCK and CAH need filed local security lanes before this page can route every company-specific claim through durable knowledge pages.
Static setup labels and thresholds remain from the 2026-06-11 package while the local chart API can see data through 2026-06-12. Refresh setup levels before using chart thresholds as current trading evidence.
CAH's next earnings date is not confirmed in this worker pass.
PBM, Medicare, reimbursement, and pharmacy-closure surfaces can change quickly. Refresh company filings and policy sources before using this page for a new decision cycle.
WBA and PDCO should stay out of charted tables unless local instruments and OHLC coverage return.